ORDER A TEST Log In Contact Us
Back TO events
January 19 — 21, 2023 San Francisco, CA

Level 1, West Hall
Tabletop 52
6 Poster Presentations

ASCO® GI Symposium 2023

Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. We are pleased to share our latest scientific and clinical research findings during the ASCO Gastrointestinal Symposium 2023.

Schedule a meeting with us
Poster Presentations
January 19, 2023
Time
12:00pm PST

Presentation Number: D7
Authors
Mary Mulcahy (Robert H. Lurie Comprehensive Cancer Center), Halla Nimeiri (Tempus), et. al.

Real-world outcome analysis of patients with advanced gastric and gastroesophageal adenocarcinoma with HER2-low expression treated with first-line therapy

HER2-low tumors are not well characterized among gastric or gastroesophageal junction adenocarcinomas. More importantly, this patient population is currently treated as HER2-negative without anti-HER-2 directed therapy. This poster leveraged Tempus’ multimodal database to describe a real-world outcome analysis of this distinct genomically defined underrepresented population.

Read more
Time
12:00pm PST

Presentation Number: L3
Authors
Sarbajit Mukherjee (Roswell Park Comprehensive Cancer Center), Elizabeth Mauer (Tempus), et. al.

Genomic and immune landscape of ERBB2/ERBB3 alterations in gastroesophageal adenocarcinoma

HER2/ERBB2 is a known therapeutic target in gastroesophageal adenocarcinoma (GEAC). HER3/ERBB3 is an emerging target in a variety of cancers but less defined in GEAC. This poster uses Tempus multimodal data to provide insights into the genomic and immunologic landscape of ERBB2/ERBB3 alterations in GEAC.

Read more
January 21, 2023
Time
06:30am PST

Presentation Number: L11
Authors
J. Hecht (UCLA), Armen Mardiros (A2 Bio), Ameen Salahudeen (Tempus), et. al.

Prospective BASECAMP-1 experience in patients with gastrointestinal (GI) cancer: Identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for a future therapeutic trial exploiting LOH as a tumor vulnerability

Both in vitro/in vivo, Tmod chimeric antigen receptor (CAR) T-cell therapy kills cells with HLA-A*02 LOH (tumor) without harming cells with retained HLA-A*02 expression (normal). However, HLA-A*02 LOH can only be therapeutically exploited if patients are identifiable through a feasible and timely clinical workflow. We established a biobanking protocol (BASECAMP-1, NCT04981119) and determined this prospective HLA-A*02 LOH identification strategy is achievable in the real-world setting.

Read more
Time
06:30am PST

Presentation Number: K9
Authors
Marwan Fakih (City of Hope National Comprehensive Cancer Center), Calvin Chao (Tempus), et. al.

Comparative analysis of tumor immune microenvironment in primary tumors vs metastatic tissue in microsatellite stable metastatic colorectal cancer

Previous research has demonstrated differences in responses to checkpoint inhibitors between liver and non-liver metastases in microsatellite stable metastatic colorectal cancer (mCRC). This poster leverages Tempus’ multimodal database to investigate differences in tumor microenvironment and mutational landscape of CRC primary and metastatic sites.

Read more
Time
06:30am PST

Presentation Number: L1
Authors
Tucker Coston (Mayo Clinic Jacksonville), Elizabeth Mauer (Tempus), Melissa Stoppler (Tempus), et al.

Charac­terizing the genomic landscape of POLE/POLD1-mutated colorectal adenocarcinoma

The progression of neoplasia in colorectal cancer (CRC) has been well characterized, with the evolution typically involving mutations in APC, KRAS, and p53, among others. POLE/POLD1 genes encode for proteins essential in enzymatic DNA polymerase function, yet POLE/POLD1 mutations in tumors are poorly characterized. This poster uses Tempus’ multimodal database to describe POLE/POLD1 alterations in a large, real-world cohort of patients with CRC.

Read more
Time
06:30am PST

Presentation Number: M13
Authors
Mohamed Salem (Levine Cancer Institute), Calvin Chao (Tempus), et al.

Comprehensive characterization of KRAS mutations and inter-relation with primary tumor location in colorectal cancers

The recent development of KRAS G12C inhibitors underscores the potential to target KRAS mutations. Right-sided and left-sided colon tumors exhibit different molecular features. This poster uses Tempus multimodal data to characterize the prevalence of KRAS variants, interrelation with primary tumor location, and association with immune biomarkers in CRC.

Read more

Schedule a meeting with us

We'll be in touch shortly.